Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice

PPARγ agonists have been proven to be neuroprotective in vitro and in vivo models of Alzheimer’s disease (AD). In the present study, we identified ligustrazine piperazine derivative (LPD) as a novel PPARγ agonist, which was detected by a dual-luciferase reporter assay system. LPD treatment dose-depe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zongyang, Meng, Xiangbao, Ma, Guoxu, Liu, Wenlan, Li, Weiping, Cai, Qian, Wang, Sicen, Huang, Guodong, Zhang, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552451/
https://www.ncbi.nlm.nih.gov/pubmed/36217155
http://dx.doi.org/10.1186/s13195-022-01092-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552451/
https://www.ncbi.nlm.nih.gov/pubmed/36217155
http://dx.doi.org/10.1186/s13195-022-01092-7

Ejemplares similares